ExLibris header image
SFX Logo
Title: Brentuximab Vedotin Combined with ABVD or AVD for Patients with Newly Diagnosed Advanced Stage Hodgkin Lymphoma: Long Term Outcomes
Source:

Blood [0006-4971] Connors, Joseph yr:2014


Collapse list of basic services Basic
Sorry, no full text available...
Please use the document delivery service (see below)  
Holding information
Holdings in library search engine ALBERT GO
Document delivery
Request document via Library/Bibliothek GO
Users interested in this article also expressed an interest in the following:
1. Zallio, F. "Efficacy of Reduced-Intensity Allogeneic Stem Cell Transplant after Brentuximab Vedotin in Patients with Hodgkin Lymphoma Relapsed after Autologous Transplant." Blood 124.21 (2014): 5943-. Link to SFX for this item
2. Forero Torres, A. "Brentuximab vedotin monotherapy and in combination with dacarbazine in frontline treatment of Hodgkin lymphoma in patients aged 60 years and above: Interim results of a phase 2 study." Blood 124.21 (2014): 294-. Link to SFX for this item
3. Jia, J. "A Case of PML after Initiation Of Brentuximab Vedotin For CD30 Positive Cutaneous T Cell Lymphoma (P7. 032)." Neurology 82.10 Supplement (2014). Link to SFX for this item
4. Anderlini, P. "Reduced-Intensity Conditioning and Allogeneic Stem Cell Transplantation For Relapsed/Refractory Hodgkin Lymphoma In The Brentuximab Vedotin Era." Biology of blood and marrow transplantation 20.2 (2014). Link to Full Text for this item Link to SFX for this item
Select All Clear All

Expand list of advanced services Advanced
A service provided by the Library of the Wissenschaftspark Albert Einstein, Potsdam, Germany.
© 2005 SFX by Ex Libris Inc.